NysnoBio
NysnoBio is a clinical-stage biotech developing Parkin-based gene therapy (NB001) and small-molecule mitophagy activators for Parkinson's disease, initially targeting patients with Parkin gene mutations. The company is pre-revenue and funded by grants from MJFF, CIRM, and ASAP.
- Company typePrivate
- Founded2019
- HeadquartersMill Valley, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What NysnoBio does
NysnoBio is a clinical-stage (IND-enabling) biotechnology company developing Parkin-based therapeutics for Parkinson's disease. The company's lead program, NB001, is an AAV-delivered Parkin gene therapy designed to restore Parkin function, with an initial focus on patients with Parkin gene mutations who present with Young Onset Parkinson's Disease. NysnoBio is also advancing small-molecule mitophagy activators (FB231 and MTK458) through its sister company FinsnoBio, which are intended to be orally bioavailable and potentially applicable to a broader Parkinson's population beyond genetically defined carriers. The company's scientific platform is built on the founders' foundational work in Parkin biology, including the discovery of Parkin's E3 ubiquitin ligase activity and the publication of its crystal structure.
NysnoBio has assembled supporting infrastructure around the core science: a non-profit subsidiary, NysnoBioMetriX (NBX), operates a centralized Parkinson's gene database developed with Data Ductus using AI-driven analytics; a partnership with Rune Labs enables wearable-based patient monitoring via the StrivePD platform; and a manufacturing partnership with Thermo Fisher Scientific supports GMP production for IND-enabling toxicology studies. Academic collaborations extend internationally to Lund University and researchers in Sydney and Melbourne. The company's leadership includes a Chairman who was formerly CEO of a public gene therapy company, a CMO with vaccine and gene therapy experience, and a CTO with operations and translational expertise.
The business model is currently pre-revenue. NysnoBio funds operations through non-dilutive grants from foundations including the Michael J. Fox Foundation (MJFF), the California Institute for Regenerative Medicine (CIRM), and the Aligning Science Across Parkinson's (ASAP) initiative, with aggregate disclosed grant funding exceeding $11 million since 2021. Future revenue, if successful, would come from licensing and eventual commercialization of Parkin-directed gene therapy and small-molecule products; the company has not disclosed pricing, payer strategy, or partnership economics. The headcount of 11-50 employees is consistent with an early clinical-stage biotech funded primarily by foundation capital.
NysnoBio firmographics
Firmographics- Name
- NysnoBio
- Legal name
- NysnoBio, LLC
- Website
- https://nysnobio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NysnoBio is a clinical-stage biotech developing Parkin-based gene therapy (NB001) and small-molecule mitophagy activators for Parkinson's disease, initially targeting patients with Parkin gene mutations. The company is pre-revenue and funded by grants from MJFF, CIRM, and ASAP.
- Ownership category
- akta.pro rank
NysnoBio industry classification
Industry- Product category
- Gene Therapy for Parkinson's Disease
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
- akta.pro secondary industries
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where NysnoBio is headquartered
LocationHeadquarters
- HQ city
- Mill Valley
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NysnoBio business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Gene Therapy Development: Pre-revenue company developing gene therapy for Parkinson's disease. Revenue will come from therapeutic product once approved and commercialized.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NysnoBio product offering
Product offeringCore offering
NysnoBio develops Parkin-based therapeutics for Parkinson's disease, with its lead candidate NB001 being an AAV-delivered Parkin gene therapy aimed at restoring dopamine neuron function and providing neuroprotection in patients with Parkin mutations. The company also develops small molecule mitophagy activators (FB231, MTK458) through sister company FinsnoBio and operates the non-profit NysnoBioMetriX (NBX) patient data platform. The pipeline is at IND-enabling stage, with manufacturing partnership at Thermo Fisher Scientific.
Product overview
NysnoBio is advancing Parkin-based therapeutics for Parkinson's disease through two complementary approaches: (1) Gene therapy using the Parkin gene (lead candidate NB001) to restore dopamine neuron function and provide neuroprotection, and (2) Small molecule mitophagy activators (FB231, MTK458) developed with sister company FinsnoBio. The company also operates NysnoBioMetriX (NBX), a non-profit data platform that provides AI-powered analytics on patient-derived genetic data to support Parkinson's research. The gene therapy pipeline is in IND-enabling stage with manufacturing partnership established at Thermo Fisher Scientific.
Differentiator
Problem solved
Functional benefit
Brands
- NysnoBioMetriX (NBX): Non-profit arm of NysnoBio focused on developing patient-centered Parkinson's Disease gene database and data analytics platform.
Products and services
- NB001 (Parkin Gene Therapy) AAV-delivered gene replacement therapy candidate for Parkinson's disease that restores dopamine neuron function and provides neuroprotection by delivering functional Parkin genes to patients with Parkin mutations. Currently in IND-enabling stage.
- Mitophagy Activators (FB231, MTK458) Small molecule mitophagy activating compounds that enhance mitophagy through a dual mechanism supporting PINK1/Parkin pathway activation, intended for Parkinson's disease treatment. Developed jointly with sister company FinsnoBio.
- NysnoBioMetriX (NBX) Database Platform Patient-centered Parkinson's disease gene database and open data-sharing platform integrating human iPSCs, complete genetic information, and patient-level data, with AI analytics tools for PD researchers. Operated by NysnoBio's nonprofit arm in partnership with Data Ductus.
Quantifiable outcome
- Parkin-PD is the most potent known genetic form of PD with almost 100% penetrance
- +1 more outcomes
Companies that use NysnoBio
Customer profileSegments2 records
Ideal customer profiles2 records
NysnoBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature4 records
NysnoBio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- FinsnoBiocoreNysnoBio and sister company FinsnoBio are jointly developing mitophagy enhancers using gene therapy and small molecule approaches based on genetic targets in Parkinson's disease.
- Thermo Fisher ScientificcoreNysnoBio started manufacturing their first product NB001 at Thermo Fisher Scientific's giant new plant in the Boston metro area (Plainville, MA). Thermo Fisher's fifth viral vector manufacturing facility is one of the largest in the world for AAV production.
- Rune LabscoreNysnoBio partner Rune Labs secured FDA clearance for Parkinson's Disease monitoring through its StrivePD ecosystem for smartwatches. This FDA-cleared monitoring allows NysnoBio to identify specific patient characteristics for genetic Parkin patients to design effective clinical trials, from patient enrollment to clinical readouts.
- Data DuctussupportingNBX (NysnoBioMetriX) partnered with Data Ductus of Sweden to build and operate the technology platform for patient-centered Parkinson's disease gene database with expertise in data analytics, AI and privacy protections.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
NysnoBio competitors and assessment
Company assessmentDirect peers
- Sio Gene Therapies: Clinical-stage gene therapy company with Parkinson's disease programs (AAV-GAD), historically focused exclusively on PD gene therapy; highly comparable in indication and modality.
- Prevail Therapeutics (a wholly owned subsidiary of Eli Lilly): AAV9-based gene therapy developer focused on neurodegenerative diseases including Parkinson's disease (LRRK2 program); acquired by Lilly in 2021. Closely comparable technology platform and CNS gene therapy approach.
- MeiraGTx Holdings: Clinical-stage gene therapy company with CNS and Parkinson's disease programs using AAV vectors, with in-house GMP manufacturing capacity. Direct competitor in AAV gene therapy for neurodegenerative indications.
- BlueRock Therapeutics (Bayer): Pioneering iPSC-derived dopaminergic neuron cell therapy for Parkinson's disease, owned by Bayer. Competes for disease-modifying PD market share with a different modality but same target indication.
- Voyager Therapeutics: Clinical-stage AAV gene therapy company developing CNS programs including Parkinson's disease treatments, sharing NysnoBio's AAV vector approach and neurodegenerative disease focus.
Emerging players
- Cerevel Therapeutics (AbbVie): Neuroscience-focused company developing CNS therapeutics including Parkinson's disease pipeline (acquired by AbbVie in 2024); adjacent competitor pursuing PD via complementary mechanisms.
- Capsida Biotherapeutics: Gene therapy company developing CNS-targeted AAV therapeutics for neurodegenerative diseases; overlapping technology class and indication focus with NysnoBio.
- Lexeo Therapeutics: Clinical-stage gene therapy company developing CNS-targeted AAV therapeutics for neurodegenerative diseases including Parkinson's, with overlapping platform technology to NysnoBio.
Broad incumbents
- uniQure: Commercial-stage AAV gene therapy company with established manufacturing infrastructure and CNS pipeline; comparable gene therapy modality with broader therapeutic focus.
- AskBio (Bayer): Established AAV gene therapy platform owned by Bayer with broad neurodegenerative pipeline including Parkinson's programs; broader portfolio than NysnoBio's focused Parkin approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
NysnoBio social profiles
Digital presenceNysnoBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
NysnoBio leadership team
Management profileNumber of profiles
Profiles8 records
NysnoBio subsidiaries and ownership
Company hierarchySubsidiaries2 records
NysnoBio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NysnoBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NysnoBio
What does NysnoBio do?
NysnoBio develops Parkin-based therapeutics for Parkinson's disease, with its lead candidate NB001 being an AAV-delivered Parkin gene therapy aimed at restoring dopamine neuron function and providing neuroprotection in patients with Parkin mutations. The company also develops small molecule mitophagy activators (FB231, MTK458) through sister company FinsnoBio and operates the non-profit NysnoBioMetriX (NBX) patient data platform. The pipeline is at IND-enabling stage, with manufacturing partnership at Thermo Fisher Scientific.
Is NysnoBio a public or private company?
NysnoBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NysnoBio founded?
NysnoBio was founded in 2019. It employs 11 to 50 people.
Where is NysnoBio based?
NysnoBio is headquartered in Mill Valley, United States, in the North America region.
How does NysnoBio make money?
One revenue line is on record: gene Therapy Development.
Who are NysnoBio's main competitors?
Direct peers on record are Sio Gene Therapies, Prevail Therapeutics (a wholly owned subsidiary of Eli Lilly), MeiraGTx Holdings, BlueRock Therapeutics (Bayer) and Voyager Therapeutics. Emerging players are Cerevel Therapeutics (AbbVie), Capsida Biotherapeutics and Lexeo Therapeutics. Broad incumbents are uniQure and AskBio (Bayer).
Does NysnoBio have an API?
No public API is recorded for NysnoBio.
What industry is NysnoBio in?
NysnoBio's product category is Gene Therapy for Parkinson's Disease. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 8731.